Furthermore, imaging (Nam et al., 2017), stroke subtype (Amarenco et al., 2016), and other biomarkers such as low‐density lipoprotein (Amarenco et al., 2006), copeptin (Greisenegger et al., 2015), homocysteine (Shi et al., 2018), and serum asymmetric dimethylarginine (Qin et al., 2021) all have been confirmed to have an association with subsequent stroke risk. Here, AVP is linked to stroke disorder.